CHENGDU, China, Sept. 14, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", 6990.HK) announced that results from the phase III registrational study of its novel human epidermal growth factor receptor 2 (HER2)-targeted antibody–drug...
Hence then, the article about results from phase iii study of trastuzumab botidotin versus t dm1 in her2 positive breast cancer published in jco was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO )
Also on site :
- What time do polls open and close in Illinois? 2026 Election Day voting guide
- Laura Dern Remembers Late Mom Diane Ladd With Heartbreaking Tribute 1 Year After Her Death: ‘Light of My Life’
- A Gastroenterologist Ate This ‘Healthy’ Snack Almost Every Day for Nearly a Decade—Now She’s Ditched It Completely